Saturday, September 23, 2023
Saturday, September 23, 2023

ZEISS Reimagined the Iconic PENTERO Platform for Today’s Digital Age

At this year’s Congress of Neurological Surgeons (CNS) in Washington D.C., USA, ZEISS Medical Technology introduces PENTERO® 800 S from ZEISS – the reimagination of the iconic PENTERO platform. The Advanced Visualization System provides Visual Certainty with extended optical capabilities to work in deep anatomical channels with more confidence and facilitates manipulation of submillimeter vessels with unprecedented resolution. Seamless Performance with reinvented interactions allows to accelerate workflow efficiency, and Integrated Connectivity with leading digital solutions supports to educate the next generation of leading surgeons, as well as communicating effectively within and outside of the OR. And ultimately, to make a real difference in the lives of the patients.

Modern microsurgery builds upon advances in providing comprehensive visual information in the right moment. “The iconic ZEISS PENTERO platform is one of the most widely used surgical microscopes around the world with more than 20 million surgical procedures to date. With the surgeons’ constantly evolving discipline-specific challenges in mind, ZEISS now reimagined it for today’s digital age to support them in elevating the microsurgical interventions to yet another level,” says Magnus Reibenspiess, Head of Strategic Business Unit Microsurgery, ZEISS Medical Technology.

Visual Certainty with extended optical capabilities

During microsurgical interventions, surgeons have to be certain that they are making the right decisions at the right time. Therefore, detailed and immediate visual information on the anatomy is key to achieve the best outcome for their patients. ZEISS PENTERO 800 S provides them with Visual Certainty at each step of the surgical procedure. It combines a fully integrated 4K 3D camera system with excellent ZEISS optics and further extends their surgical view with refined resolution, enhanced depth of field, and around-the-corner perspectives. “[…] In spine surgery what we are looking for is really a combination of visualization technologies using the exoscope, the microscope, the QEVO* […] together allowing us to do surgeries less invasively, more accurately, and more precisely,” states Dr. Roger Haertl, MD, Director of Spinal Surgery at Weill Cornell Medicine Center for Comprehensive Spine Care, New York, USA.

Seamless Performance with reinvented interactions

For an outstanding performance, an intuitive handling and repositioning of the operating microscope is not only imperative but key to maintain constant focus on the patient and application at hand.

For the ZEISS PENTERO 800 S, ZEISS optimized each and every device interaction alongside the clinical workflows and attuned it to surgeon’s intuition. Combining the new user interface with the characteristic weightless movability of the PENTERO system, it becomes the trusted partner for real efficiency and seamless collaboration in the OR in no time.

Integrated Connectivity with leading digital solutions

With the rise of digital technology in the OR, surgical procedures today involve processing large amounts of data, from patient information to device settings to clinical recordings. Especially in the day-to-day routine with the operating microscope, being able to easily transfer and use the data instantly across systems is essential for smooth and efficient processes. With ZEISS PENTERO 800 S, surgeons can exploit the full potential of the digital era – now and in the future. The Advanced Visualization System enables access to leading digital solutions from ZEISS to simplify data management and facilitate peer collaboration and education. Apps such as ZEISS Surgical Cloud and ZEISS Livestream support to effectively store, share, and stream clinical cases directly from the device. All while connecting seamlessly into the existing workflows and infrastructure.

ZEISS PENTERO 800 S opens up the next chapter in this success story of the iconic platform.
The Advanced Visualization System offers a multitude of options to assist surgeons during surgery for increased efficiency and effectiveness to make a real difference in the lives of their patients.

* not for sale in the USA

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy